{
    "nct_id": "NCT03979508",
    "official_title": "Window Trial of Abemaciclib for Surgically Resectable, Chemotherapy-Resistant, Triple Negative Breast Cancer (a BEAUTY Study*)",
    "inclusion_criteria": "* Women of age >=18 years\n* PRE-REGISTRATION: Clinical T1-4, N0-3, M0 breast cancer at diagnosis (prior to the start of neoadjuvant chemotherapy) by American Joint Committee on Cancer (AJCC) staging version 8.\n\n  * Note: Benign breast disease, lobular carcinoma in situ (LCIS) or ductal carcinoma in situ (DCIS) in the ipsilateral or contralateral breast is allowed.\n  * Note: Additional ipsilateral or contralateral invasive breast cancer is allowed. The index lesion is the largest triple-negative, chemotherapy-resistant lesion.\n* PRE-REGISTRATION: Histological confirmation of triple negative invasive breast cancer (defined as estrogen receptor [ER] =< 10%, progesterone receptor [PR] =< 10% and HER2 not amplified by in situ hybridization [ISH] or immunohistochemistry [IHC] 0/1) at diagnosis.\n* PRE-REGISTRATION: Cohort A: CLOSED TO PRE-REGISTRATION and REGISTRATION as of protocol amendment 6 (04/14/2023) Neoadjuvant chemotherapy (NAC) with one of the following regimens that was not discontinued early due to intolerability with less than 50% of planned treatment given due to disease progression or patient request:\n\n  * Paclitaxel or docetaxel followed by one of the following: the combination of doxorubicin and cyclophosphamide (AC); the combination of epirubicin and cyclophosphamide (EC) or the combination of 5-fluorouracil, epirubicin and cyclophosphamide (FEC)\n\n    * Note: Carboplatin may be added to these regimens\n  * AC or EC or FEC followed by docetaxel or paclitaxel\n\n    * Note: Carboplatin may be added to these regimens\n  * Docetaxel in combination with doxorubicin and cyclophosphamide (TAC)\n  * Docetaxel in combination with cyclophosphamide (TC) (for patients who are not candidates for anthracyclines)\n  * Carboplatin or cisplatin in combination with a taxane (paclitaxel, docetaxel, or nab-paclitaxel) (for patients who are not candidates for anthracyclines)\n* PRE-REGISTRATION: Cohort B: Neoadjuvant chemotherapy (NAC) with one of the following regimens in combination with pembrolizumab that was not discontinued early due to intolerability with less than 50% of planned treatment given due to disease progression or patient request:\n\n  * Paclitaxel or docetaxel followed by one of the following: the combination of doxorubicin and cyclophosphamide (AC); the combination of epirubicin and cyclophosphamide (EC) or the combination of 5-fluorouracil, epirubicin and cyclophosphamide (FEC) Note: Carboplatin may be added to these regimens\n  * AC or EC or FEC followed by docetaxel or paclitaxel [Note: Carboplatin may be added to these regimens]\n  * Docetaxel in combination with doxorubicin and cyclophosphamide (TAC)\n  * Docetaxel in combination with cyclophosphamide (TC)\n  * Carboplatin or cisplatin in combination with a taxane (paclitaxel, docetaxel, or nab-paclitaxel)\n* PRE-REGISTRATION: Residual lesion/enhancement seen in the breast on breast imaging performed after completion of NAC.\n* PRE-REGISTRATION: Able to swallow oral medication.\n* PRE-REGISTRATION: Willing to undergo biopsy for research.\n* PRE-REGISTRATION: Willing to provide tissue and blood samples for correlative research purposes.\n* PRE-REGISTRATION: Willing to stop use of strong and moderate inducers and/or strong inhibitors of cytochrome P450 3A =< 7 days prior to registration.\n* PRE-REGISTRATION: Provide written informed consent.\n* REGISTRATION: Registration must occur =< 56 days after last dose of NAC.\n* REGISTRATION: Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1, or 2.\n* REGISTRATION: COHORT B GROUP 4 ONLY: The following laboratory values obtained after completion of NAC but =< 14 days prior to registration:\n* REGISTRATION: COHORT B GROUP 4 ONLY: Absolute neutrophil count (ANC) >= 1500/mm^3.\n* REGISTRATION: COHORT B GROUP 4 ONLY: Platelets (PLT) >= 100,000/mm^3.\n* REGISTRATION: COHORT B GROUP 4 ONLY: Hemoglobin (HgB) >= 8.0 g/dL.\n* REGISTRATION: COHORT B GROUP 4 ONLY: Total bilirubin =< 1.5 x upper limit of normal (ULN).\n* REGISTRATION: COHORT B GROUP 4 ONLY: Aspartate transaminase (AST) serum glutamic oxaloacetic transaminase (SGOT) =< 3 x ULN.\n* REGISTRATION: COHORT B GROUP 4 ONLY: Alanine transaminase (ALT) serum glutamate pyruvate transaminase (SGPT) =< 3 x ULN.\n* REGISTRATION: COHORT B GROUP 4 ONLY: Serum creatinine =< 1.5 x ULN.\n* REGISTRATION: GROUP 2 ONLY: Negative pregnancy test done =< 7 days prior to registration, for persons of childbearing potential only.\nHealthy volunteers allowed\nMust be FEMALE\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* PRE-REGISTRATION: History of deep venous thrombosis (DVT) or pulmonary embolisms (PE) =< 12 months prior to preregistration; OR Active DVT and/or PE requiring anti-coagulant therapy.\n\n  * NOTE: Patients who are on anti-coagulant therapy for maintenance are eligible as long as the DVT and/or PE was > 12 months prior to enrollment and there is no evidence for active thrombosis (either DVT or PE).\n  * NOTE: Patients on anticoagulation are eligible; however peri-biopsy and peri-surgical management of anticoagulation is per the institutional standard of care.\n* PRE-REGISTRATION: Prior treatment with CDK 4/6 inhibitors (e.g. palbociclib, ribociclib, abemaciclib, etc.)\n* PRE-REGISTRATION: Prior treatment with radiation for this breast cancer.\n* PRE-REGISTRATION: Prior incisional or excisional breast biopsy for this cancer.\n* PRE-REGISTRATION: Any contraindications to pre-registration biopsy (such as bleeding diatheses, etc.).\n* PRE-REGISTRATION: Receiving any investigational agent which would be considered as a treatment for the primary neoplasm.\n* PRE-REGISTRATION: Other active malignancy =< 3 years prior to registration.\n\n  * EXCEPTIONS: Non-melanotic skin cancer or carcinoma-in-situ of the cervix.\n  * NOTE: If there is a history of prior malignancy, they must not be receiving another specific treatment for prior malignancy.\n* PRE-REGISTRATION: Biopsy proven Stage IV breast cancer.\n* PRE-REGISTRATION: Serious pre-existing medical conditions that would preclude participation in this study (for example, interstitial lung disease, severe dyspnea at rest or requiring oxygen therapy, severe renal impairment [e.g., estimated creatinine clearance < 30 ml/min], history of major surgical resection involving the stomach or small bowel, or preexisting Crohn's disease or ulcerative colitis or a preexisting chronic condition resulting in baseline grade 2 or higher diarrhea).\n* PRE-REGISTRATION: History of any of the following conditions:\n\n  * Syncope of cardiovascular etiology.\n  * Ventricular arrhythmia of pathological origin (including, but not limited to, ventricular tachycardia and ventricular fibrillation).\n  * Sudden cardiac arrest.\n  * NOTE: Patients on anticoagulation are eligible; however peri-biopsy and peri-surgical management of anticoagulation is per the institutional standard of care.\n* REGISTRATION: COHORT B GROUP 4: Any of the following because this study involves an investigational agent whose genotoxic, mutagenic and teratogenic effects on the developing fetus and newborn are unknown:\n\n  * Pregnant persons.\n  * Nursing persons.\n  * Persons of childbearing potential who are unwilling to employ adequate contraception.\n* REGISTRATION: COHORT B GROUP 4: Failure to recover to grade 1 or lower from effects of neoadjuvant chemotherapy.\n\n  * Exceptions: Residual alopecia and grade 2 peripheral neuropathy are allowed.\n* REGISTRATION: COHORT B GROUP 4: Concurrent use of strong and moderate inducers and/or strong inhibitors of cytochrome P450 3A =< 7 days prior to registration.\n* REGISTRATION: COHORT B GROUP 4: Known infections as follows (NOTE: Screening is not required for enrollment):\n\n  * Active systemic bacterial infection requiring intravenous antibiotics.\n  * Active fungal infection (requiring intravenous or oral antifungal treatment).\n  * Detectable viral infections (e.g. known human immunodeficiency virus [HIV], known active hepatitis B or C).\n* REGISTRATION: COHORT B GROUP 4: Concurrent use of chemotherapy, radiotherapy, immunotherapy, or other components of neoadjuvant treatment.\n\n  * NOTE: Patients must complete all elements of NAC â‰¥21 days prior to starting abemaciclib.",
    "miscellaneous_criteria": ""
}